趋化因子受体是一类G蛋白偶联的7次跨膜受体,其与配体结合能参与调控多种生理和病理学过程。以往,CXCR4一直被认为是趋化因子CXCL12的唯一受体。然而近年来的研究表明CXCL12能与另一种新受体CXCR7结合,并在调控肿瘤转移、血管生成和细胞粘附等方面起着重要作用,CXCR7由此成为肿瘤治疗的潜在靶点。介绍CXCR7的结构、生物学功能以及CXCR7在肿瘤发生发展中的作用。 Chemokine receptors are a class of G-protein coupled 7-transmembrane receptors that bind to ligands and are involved in the regulation of various physiological and pathological processes. In the past, CXCR4 has long been considered the only receptor for the chemokine CXCL12. However, recent studies show that CXCL12 binds to another novel receptor, CXCR7, and plays an important role in the regulation of tumor metastasis, angiogenesis and cell adhesion. CXCR7 has become a potential target for tumor therapy. The structure, biological function and the role of CXCR7 in tumorigenesis were introduced.